BioStem Technologies (OTCMKTS:BSEM) Trading Up 2.3% – What’s Next?

BioStem Technologies, Inc. (OTCMKTS:BSEM)’s stock price traded up 2.3% on Tuesday . The company traded as high as $4.04 and last traded at $3.98. 95,602 shares traded hands during mid-day trading, an increase of 183% from the average session volume of 33,738 shares. The stock had previously closed at $3.89.

Wall Street Analyst Weigh In

Separately, HC Wainwright assumed coverage on shares of BioStem Technologies in a report on Wednesday, May 6th. They set a “buy” rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $9.00.

BioStem Technologies Price Performance

The firm has a fifty day simple moving average of $3.86 and a two-hundred day simple moving average of $4.72. The firm has a market capitalization of $70.96 million, a P/E ratio of -3.57 and a beta of 0.11.

BioStem Technologies (OTCMKTS:BSEM) last issued its earnings results on Thursday, May 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The business had revenue of $6.14 million during the quarter, compared to analysts’ expectations of $5.70 million. On average, research analysts anticipate that BioStem Technologies, Inc. will post -1.95 EPS for the current year.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.